Orient EuroPharma Co., Ltd. (4120) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Orient EuroPharma Co., Ltd. (4120:TWSE), powered by AI.

Current Price
$45.40
Sector
Healthcare
What is the Orient EuroPharma Co., Ltd. stock price forecast?

Orient EuroPharma Co., Ltd. is currently trading at $45.40. View real-time AI analysis on Alpha Lenz.

What is Orient EuroPharma Co., Ltd. insider trading activity?

View the latest insider trading data for Orient EuroPharma Co., Ltd. on Alpha Lenz.

What is Orient EuroPharma Co., Ltd.'s P/E ratio?

View Orient EuroPharma Co., Ltd.'s valuation metrics on Alpha Lenz.

Orient EuroPharma Co., Ltd.

TWSE · 4120
NT$45.40+0.00(+0.00%)
Ask about Orient EuroPharma Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Orient EuroPharma Co., Ltd.'s ROE is -9.9%. Explore profitability and growth together.

Ask for details

Company Overview

Orient EuroPharma Co., Ltd. is a publicly listed healthcare company specializing in the manufacturing and distribution of pharmaceuticals, health foods, and cosmetics. Established in 1982 and headquartered in Taipei, it operates primarily within the health technology sector, with a focus on the major pharmaceuticals industry. The company’s operations are divided into two main segments: the Western Medicine Section, which has demonstrated consistent revenue growth, and the Nutrition and Health Sector, which addresses consumer wellness trends and dietary supplementation needs. Orient EuroPharma’s product footprint spans key markets in Taiwan, Southeast Asia, and China, illustrating its regional influence and diversified revenue streams. The company serves hospitals, pharmacies, and health retail channels, liaising closely with healthcare professionals. Despite operating in a highly competitive landscape marked by regulatory scrutiny and rapid innovation, Orient EuroPharma maintains a significant market presence supported by a broad product portfolio and strategic international expansion. Its contributions underpin advancements in patient care and health maintenance across several Asian markets, emphasizing both pharmaceutical rigor and consumer health awareness.

CEOMr. Peter Tsai
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$4.60BRevenue
0.00Shares Out
0Employees

Margins

48.69%Gross
0.23%EBITDA
-6.50%Operating
-5.94%Pre-Tax
-10.45%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

-0.96%Rev 3Yr
-3.12%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-4.04%ROA
-9.91%ROE
-1.67%ROIC

Financial Health

NT$1.95BCash & Cash Equivalents
NT$2.90BNet Debt
66.01%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Orient EuroPharma Co., Ltd. (ticker: 4120) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic).

The current price is 45.4 with a P/E ratio of -x and P/B of -x.

ROE is -9.91% and operating margin is -6.50%. Annual revenue is $4.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Orient EuroPharma Co., Ltd. (4120) Stock Forecast 2026 $45.40 — Price, Financials & Analyst Targets | Alpha Lenz